Celcuity Inc.
Celcuity Inc. (Nasdaq: CELC) is a clinical-stage biotechnology company developing targeted therapies for solid tumors. Its lead candidate, gedatolisib, is an intravenous inhibitor of all class I PI3K isoforms and the mTORC1 and mTORC2 complexes in the PI3K/AKT/mTOR pathway. The company is studying gedatolisib… From the company’s description.
In fiscal 2025, Celcuity Inc. reported a net loss of $177.04M. Operations used $153.28M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Celcuity Inc. does
In the company’s own words
Celcuity Inc. (Nasdaq: CELC) is a clinical-stage biotechnology company developing targeted therapies for solid tumors. Its lead candidate, gedatolisib, is an intravenous inhibitor of all class I PI3K isoforms and the mTORC1 and mTORC2 complexes in the PI3K/AKT/mTOR pathway. The company is studying gedatolisib primarily for hormone receptor-positive, HER2-negative advanced breast cancer, including in combination with fulvestrant and, in some trials, a CDK4/6 inhibitor. Its Phase 3 VIKTORIA-1 trial evaluates treatment after progression on prior CDK4/6 therapy, while Phase 3 VIKTORIA-2 evaluates a first-line combination for endocrine treatment-resistant disease. A Phase 1b/2 trial is evaluating gedatolisib with darolutamide in metastatic castration-resistant prostate cancer. The FDA accepted Celcuity’s New Drug Application for gedatolisib in January 2026 and designated it for Priority Review. As of December 31, 2025, 1,127 patients and healthy volunteers had received gedatolisib in company-sponsored clinical trials.
Company details
- Sector
- Health Care
- Industry (SIC)
- Health Services
- Headquarters
- MINNEAPOLIS, MN
- Fiscal year end
- December
- CIK
- 1603454
- SIC
- 8071
Financial performance, year by year
Fiscal 2017–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Celcuity Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Celcuity Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Celcuity Inc.’s bonds, as funds hold them
Funds report holding 2 issues of Celcuity Inc.’s debt, $50.98M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 1.06%, maturing 2031 to 2032.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Celcuity Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Celcuity Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Celcuity Inc.'s last four quarterly filings that the numbers alone won't show?”